Annals of internal medicine

• Latest
• Best
• Search…

• Ann. Intern. Med. · Nov 2023

  Comment

  In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding.

  Gragnano F, Cao D, Pirondini L, et al; PANTHER Collaboration. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82:89-105. 37407118.

  read more… mark as read…

• Ann. Intern. Med. · Nov 2023

  Comment

  Thiazides do not affect mortality but may reduce CV events vs. nondiuretic antihypertensive drugs at up to 5 y.

  Reinhart M, Puil L, Salzwedel DM, et al. First-line diuretics versus other classes of antihypertensive drugs for hypertension. Cochrane Database Syst Rev. 2023;7:CD008161. 37439548.

  read on… or not…

• Ann. Intern. Med. · Nov 2023

  Comment

  In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y.

  So H, Lam TO, Meng H, et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82:1387-1393.37487608.

  explore further… mark as read…

• Ann. Intern. Med. · Nov 2023

  Letter

  Age at Diagnosis in U.S. Adults With Type 1 Diabetes.

  no abstract available

  read more… or not…

• Ann. Intern. Med. · Nov 2023

  Editorial

  Submitting Your Work to Annals: Author-Friendly Features.

  no abstract available

  keep reading… or not…